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Abstract: Osteoarticular pathologies very often require an implementation therapy to favor 
regeneration processes of bone, cartilage and/or tendons. Clinical approaches performed on 
osteoarticular complications in dogs constitute an ideal model for human clinical 
translational applications. The adipose-derived mesenchymal stem cells (ASCs) have 
already been used to accelerate and facilitate the regenerative process. ASCs can be 
maintained in vitro and they can be differentiated to osteocytes or chondrocytes offering a 
good tool for cell replacement therapies in human and veterinary medicine. Although 
ACSs can be easily obtained from adipose tissue, the amplification process is usually 
performed by a time consuming process of successive passages. In this work, we use 
canine ASCs obtained by using a Bioreactor device under GMP cell culture conditions that 
produces a minimum of 30 million cells within 2 weeks. This method provides a rapid and 
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aseptic method for production of sufficient stem cells with potential further use in clinical 
applications. We show that plasma rich in growth factors (PRGF) treatment positively 
contributes to viability and proliferation of canine ASCs into caprolactone  
2-(methacryloyloxy) ethyl ester (CLMA) scaffolds. This biomaterial does not need 
additional modifications for cASCs attachment and proliferation. Here we propose a 
framework based on a combination of approaches that may contribute to increase the 
therapeutical capability of stem cells by the use of PRGF and compatible biomaterials for 
bone and connective tissue regeneration. 
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1. Introduction 
In the field of regenerative medicine, an increasing number of strategies propose a combination of 
different therapeutic approaches that have improved the regeneration process when applied alone. 
Numerous strategies of tissue engineering presently under development in humans and animals include 
transplants of stem cells to regenerate damaged tissues and organs and constitute a promising approach 
for bone and adjacent tissues regeneration [1]. The use of mesenchymal stem cells to repair bones and 
joint tissues, such as cartilage and tendon, offers therapeutic alternatives [2,3] and constitute a real 
hope for the use in traumatic, degenerative and inflammatory disorders associated with these 
tissues [4,5]. Adipose-derived stem cells (ASCs) constitute a source of stem cells of easy and rapid 
isolation from adipose tissue that can differentiate to multiple lineages, including osteoblast and 
chondrocytes [6–8]. Non-aggressive invasive biopsy from subcutaneous adipose tissue and  
suction-assisted lipectomy (liposuction) are frequent techniques used to obtain adult adipose-derived 
stem cells. New approaches for ASC amplification and isolation are being developed [8,9]. Their main 
goal is to generate sufficient number of stem cell for clinical applications, including autologous 
transplantation approaches that would avoid undesired immunoreactions. In fact, during last decade, 
much effort is being implemented to increase the yield, efficiency and therapeutical capability of stem 
cells, including the use of different growth factors as those associated with platelet rich plasma growth 
factors (PRGF) [10]. PRGF might constitute an autologous source of growth factors (GFs) that can 
contribute to tissue regeneration [11,12]. In fact, PRGF contains GFs that induce growth of 
mesenchymal stem cells (MSCs) and osteogenic lineage cells which can accelerate bone repair [13]. 
Therefore, a combination of ASCs and PRGF can produce a synergistic effect to increase the yield on 
bone formation and consolidation [14]. Additional strategies in tissue engineering in osteoarticular 
pathologies involve a combination of ASCs with coral scaffolds resulting in the successful repair of 
canine bone defects [1]. Moreover, a variety of polymeric scaffolds for replacement into the injured 
tissue has been of interest for several research groups during the last decade. In fact, the scaffold 
biocompatibility within the tissue environment has already been for different materials (reviewed 
in [15,16]). A variety of naturally derived and synthetic biomaterial scaffolds have been investigated 
as 3D environments for supporting stem cell growth. Natural biomaterials are often composed of 
elements found in the extracellular matrix that favor cell adhesion that improve cell culture and usually 




show biodegradability. Synthetic scaffolds can be synthesized to have a greater range of mechanical 
and chemical properties often offer greater reproducibility are easy to manipulate and have no risk of 
viral infection. Additionally, they can be reproducibly manufactured on a large scale, with a variety of 
specific properties. Despite good biocompatibility of biomaterials, many synthetic scaffolds lack  
cell-adhesive properties and need additional modifications to allow cell-surface interactions. 
Caprolactone 2-(methacryloyloxy) ethyl ester (CLMA), allows enhanced cellular adhesion and 
proliferation [17]. CLMA generates scaffolds with controlled porosity for tissue engineering [18] that 
may favor the integration of stem cells in the damaged tissue that after differentiation would allow 
sites for regeneration in osteoarticular –related pathologies. ASCs isolated under aseptic conditions 
and amplified in GMP clinical-compatible criteria allow for better translational applications. Here we 
propose to create a biological and synergistic framework formed by a combination of PRGF, that 
positively contribute to the survival of cASCs, and the use of biomaterial scaffolds of CLMA as a 
compatible platform to fill the gap in the damaged tissue for optimal recovery.  
2. Results and Discussion 
2.1. Canine ASC Isolation and Characterization 
Tissue engineering has become a promising strategy to overcome the limitations of autologous 
transplants for therapeutical applications and has grown exponentially in the last two decades. The 
usual approaches propose to transplant active elements such as cells for gene-therapy, stem cells or 
proteins within a porous degradable material known as a scaffold. Since stem cells are naturally 
engrafted in active 3D microenvironments in vivo, current tissue engineering approaches often try to 
mimic the stem cells niche. Many proposed methods for engineering replacement tissues accurately 
mimic these microenvironments by culturing stem cells in 3D biomaterial scaffolds. In general, 3D 
scaffolds provide an appropriate establishment of cell polarity in the environment and possess 
biochemical and mechanical properties similar to the damaged tissue. Here we obtained cASC under 
aseptic conditions to be amplified following GMP criteria compatible for clinical use. cASCs were 
obtained from five different dogs after inguinal fat biopsy. Twenty grams of subcutaneous fat were 
processed enzymatically (collagenase) washed and centrifuged several times until obtaining a cell 
concentrate in sterilized conditions. cASC enrichment and expansion, containing autologous serum in 
the growth medium, was achieved by the use of a Bioreactor with temperature, oxygen and CO2 
controlled (Soluciones Bioregenerativas-Proteal, Barcelona, Spain). A minimum of 30 million cells are 
delivered within 2 weeks providing a rapid and aseptic method for stem cells production and further 
use in clinical applications. Two weeks after fat biopsy the concentrated cell suspension was further 
characterized by using CD90 as a stem cell marker. Flow cytometry analysis showed that half of the 
population at passage 0 positively reacts to CD90 hybridization (Figure 1a). CD34 (hematopoietic cell 
marker) hybridized with almost 40% of the remaining cell population (data not shown). Subsequently 
passages of cASCs in adherent conditions significantly enriched the CD90 positive population up to 
P5 (Figure 1a). Morphological analysis of cASC after three consecutive passages showed feature 
correlation and resemblance to mesenchymal stem cells (Figure 1b, upper panels). cASCs obtained 
from five different dogs were seeded (5 × 105 cells) and counted after three consecutive passages. A 




consistent and exponentially growing proliferative curve was found for all tested samples in growth 
medium containing 10% fetal bovine serum (Figure 1b).  
Figure 1. Canine adipose-derived mesenchymal stem cells (cASC). (a) Flow cytometry 
analysis of CD90 positive population of ASC at passages 0 (before adherent cell culture 
conditions), and passages 3 and 5 (in adherent conditions). * P < 0.05; (b) Upper panels: 
phase contrast microscopy representative images of ASC grown in adherent conditions at 
P1-3. Lower panel: Cell growth curve of ASC quantified from five independent samples at 
P1-3 and values were expressed as mean ± S.D. * P < 0.05.  
 
 
2.2. Influence of PRGF in cASC Growth 
The use of PRGF constitutes a source of cell signaling molecules and can contribute to tissue 
regeneration [11,12], also in combination with stem cells to reduce the time of consolidation in 
distraction osteogenesis [19]. Since PRGF represents a source of growth factors, it can favor the 
adhesion and proliferation of mesenchymal stem cells on 3D ceramic scaffolds [20]. However, the 
benefits of PRGF are still under evaluation since inconsistent results have been reported. This 
controversy may be caused by individual variation in growth factor concentration in PRGF [21]. We 
determined the effects of increasing concentrations (1%, 5% and 10%) of PRGF in cASCs 
proliferation. Confluent cultures were reached when cASCs were treated with 5% PRGF for 24 hours 
(Figure 2a). Untreated cells and those treated with PRGF (5%) were stained with Giemsa to improve 
visualization (Figure 2a). Significantly increased proliferation (P ≤ 0.05) of cASCs after treatment 
with 1%, 5% and 10% PRGF was quantified by MTS assay (Promega, USA) (Figure 2b). 
Transcriptional expression of the pluripotent markers Nanog, Sox2 and Oct4 was evaluated by  
semi-quantitative PCR. We detected higher presence of transcripts for all three pluripotent markers 
when cASCs where treated with 5% PRGF for 24 hours that suggests a higher self-renewal of cASCs 
(Figure 2c). A cultured supplement composed of 3% human platelet-poor plasma (hPPP) with a 
cytokine cocktail formed by epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and 
platelet-derived growth factor-bb (PDGFbb) improves ASC proliferation more than FBS. The addition 
of hPRGF to the described supplement or hPRGF alone also increases ASC expansion [10]. In line 




with these results, we observed that treatment of cASCs with a combination of FBS with PRGF does 
not change cell viability rates in comparison to those obtained with PRGF alone (Figure 2d). 
Therefore, our results suggest that growth factors contained in PRGF might be sufficient to improve 
the yield of cASCs. 
Figure 2. Plasma rich in growth factors (PRGF) treatment induce ASC proliferation.  
(a) Phase contrast microscopy images of cASC evidence an increased cell density in the 
presence of PRGF (1%, 5% or 10%) in a PRGF dose dependent manner (a–e; non-fixed 
and non-stained cells, e–f: fixed and stained with Giemsa); (b) Quantification of the 
proliferative activity of cASC in the presence or absence of PRGF (0, 1, 5 or 10%) for 
24 hours, * P < 0.05 vs. 0% PRGF. The mean ± S.D. of three different experiments is 
represented; (c) Semiquantitative PCR stemness-related gene expression in cASC treated or 
not with PRGF (5%); (d) Quantification of the proliferative activity of cASC in the presence 
or absence of 1% PRGF for 24 hours, with or without FBS (10%) in the growth medium.  
* P < 0.05 vs. 0% PRGF. The mean ± S.D. of three different experiments is represented. 
 
 
2.3. cASCs Exhibit Improved Adaptation to CMLA Scaffolds and Higher Proliferation When Treated 
with PRGF  
To our knowledge, there is a lack of proposals that combine stem cells, scaffolds and the PRGF, an 
optimal autologous source of growth factors. For instance, dental implants, using tissue engineered 
bone with natural fibrin scaffolds, stem cells and PRGF alone or in combination was previously 




proposed in dog [22]. The authors show a significant increase of bone-implant contact in dogs treated 
with a combination of mesenchymal stem cells, PRGF and fibrin. Fibrin has many advantages as a cell 
delivery vehicle in terms of biocompatibility, biodegradation and hemostasis [23,24] and can provide a 
permissive environment for cell growth with increased proliferation and survival of human bone 
marrow stromal cells in porous scaffolds [25]. This bioactive factor/scaffold has disadvantages when 
used as scaffolds, such as low rigidity that can produce shrinkage of scaffols and rapid degradation that 
would not permit proper bone regeneration. Therefore, other proposals suggest the use of fibrin as an 
adjunt element for sustaining osteogenic capacity of stem cells in mineralized scaffolds [26]. PRGF 
has also been considered as a natural scaffold [19] with advantages such as flexibility, non toxic, no 
immune reaction, complete resorption [27,28]. However, the use of PRGF as a gel can present similar 
disadvantages to fibrin.  
A more consistent material such as those formed by synthetic materials might be required for bone 
regeneration. Pieri and colleagues propose the use of mesenchymal stem cells, platelet-rich plasma and 
fluorohydroxyapatite (FH) scaffold [29]. In general, FH is a main component of bone mineral and 
accepted as a bioactive material with biocompatibility with hard tissues [30], despite its low 
degradation rate, mechanical strength and osteoinductive potential [7,8]. Autologous mesenchymal 
stem cells loaded onto porous ceramic cylinders of hydroxyaparite (65%) and p-tricalcium phosphate 
ceramic (35%) promoted faster consolidation of the fracture [31]. No additional growth factor 
enrichment was performed in this work and the observed high fold increase in the number of 
mesenchymal stem cells was explained through the culture expansion process. However, this is a time 
consuming process and porous ceramic presents a load-bearing capacity for stem cells and tends to 
fracture affected bones in dogs. Adequate cell adhesion to biomaterial implants is critical for a proper 
cell supply into the hosted tissue. Although porous scaffolds for bone tissue engineering present good 
biocompatibility and can be integrated with biological cells or molecules to regenerate tissues [32], 
some synthetic biomaterials need a previous additional modification to allow cell-surface interactions 
and improve adhesion properties of cells.  
Caprolactone 2-(methacryloyloxy) ethyl ester (CLMA), has previously allowed enhanced cellular 
adhesion and proliferation [17]. CLMA generates scaffolds with controlled porosity for tissue 
engineering [18] that may favor the integration of stem cells in the damaged tissue that would allow bone 
regeneration after differentiation. In fact, cASCs are able to adhere to CLMA (Figure 3a–c) without 
additional modifications of CMLA. cASCs cultured in CMLA were distributed throughout the scaffold 
and showed positive proliferative activity when treated with PRGF (Figure 3d–f). 
cASCs seeded on CMLA and treated with 1% PRGF showed higher yield in comparison to cells 
cultured on scaffolds without PRGF (Figure 3d,e). Cell proliferation was quantified by counting 
Phospho-Histone H3 positive cells (mitotic marker) by immunocytochemistry. There were 
significantly more phospho-histone H3-positive cells in cultures treated with 1% PRGF (Figure 3f). 
3. Experimental Section  
3.1. Adipose Tissue Processing and Derived-mesenquimal Stem Cell Culture  
A biopsy of 20 g of inguinal subcutaneous fat from five owner dogs with EPA (Early Psoriatic 
Arthritis) and 120 ml of blood were isolated in sterilized conditions and processed by using the kit 




DogStem® distributed by Soluciones Bioregenerativas-Proteal (Barcelona, Spain) following its 
manufacturer instructions. Immediately after sample collection, fat biopsy and blood (in anti-coagulant 
container) were sent at 4 °C for cell isolation and amplification in GMP conditions. Two weeks after 
biopsy, we analyzed the isolated and concentrated cells. The cells were maintained in growth medium: 
DMEM (Life Technologies S.A., Alcobendas, Spain) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin at  
37 °C, 20% O2 and 5% CO2. All cell analysis was performed up to passage 8. All the sample collection 
was approved and certified by the dog owners with an informed consent. 
Figure 3. PRGF treatment induces cASC proliferation in a methacrylate-endcapped 
caprolactone (CLMA) porously network. (a–c) Ultrastructural view of cASC seed onto 
CLMA scaffolds by scanning electron microscope; (d–e). Confocal images show 
immunolocalization of vimentin (stem-cell marker, green), P-Histone H3 (mitotic marker, 
red) and DAPI (nuclear marker, blue) in cASC-CLMA scaffolds treated or not with PRGF; 
(f) Quantification of P-Histone H3 positive cASC-CLMA cells treated or not with PRGF. 
At least 6 different fields of 3 different experiments were quantified and the mean ± S.D. is 
represented. *P < 0.05 vs. 0% PRGF. 
 
 
3.2. FACS Analysis 
ASC suspension was assayed for cell surface protein expression by flow cytometry (FC500, Cultek, 
Madrid, Spain). Cells at passage 0, 1, 3 and 5 were pelleted, resuspended in PBS at a concentration of 
105 cells/µL, and stained with 1:50 dilution of CD90 antibody conjugated with PE (BD Pharmigen, 
New Jersey, USA). Cells were incubated in the dark for 45 min at room temperature and then washed 
three times with PBS and resuspended in 0.3 mL of cold PBS for FACS analysis. The  
mean ± S.D. of the 5 different tested samples were determined.  




3.3. PRGF Preparation and ASC Viability and Proliferation 
The PRGF, isolated from three different dogs, were prepared following the standardized method 
previously described by Anitua and collegues [33]. The cell viability and proliferative activity was 
determined by The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega Co., 
Madison, WI, USA) following the manufacturer´s instructions. Briefly, 105 ASC at passages 2–5 were 
seeded onto 96 well plates and were allowed to grow for 24 hours in growth medium. After removing 
the growth medium the cells were treated with different concentrations of PRGF: 0%, 1%, 5% or 10% 
in the presence or absence of 10% FBS and 2 Units/ml of heparin for 24 hours. Every condition was 
assayed in quadruplicate in three different experiments. The viability of cells at each assayed condition 
was expressed as the percentage ratio of the mean ± S.D. of colorimetric signal from treated cells in 
the presence of PRGF in comparison with cells in the absence of PRGF. 
The proliferative curves were assayed in growth medium (in the presence of 10% FBS). ASCs  
(5 × 105) were seeded in 100 cm2 petri dishes and every third day trypan blue exclusion cell counting 
in a neubauer® chamber was performed up to passage 5. The mean ± S.D. of absolute numbers of 
viable cells of the 5 different samples was determined.  
3.4. RNA Isolation and Semiquantitative RT-PCR 
Total RNA was extracted by using the RNeasy Mini-kit (Qiagen, Germany) according to the 
manufacturer’s instructions. One µg of total RNA was reverse-transcribed in a total reaction volume of 
50 µL at 42 °C for 30 min using random hexamer primers. The semi-quantitative PCR amplification 
was performed on a thermal cycler (Eppendorf, Germany) by using the following program, 3 min of 
denaturation at 95 °C followed by 30 cycles of 30 seconds at 95 °C, 15 seconds at 60 °C, 60 second at 
72 °C and a final extension step at 72 °C for 4 minutes. The following primer sequences were used 
sequences: Sox2-Fw_5' AGTCTCCAAGCGACGAAA AA; Sox2-Rv_5': GCAAGAAGCCTCTCC 
TTGAA; Nanog-Fw_5': GAATAACCCGAATTGGAGCAG; Nanog-Rv_5': AGC GAT TCC TCT 
TCA CAG TTG; Oct4-Fw_5': GAGTGAGAGGCAACCTGGAG; Oct4-Rv_5´: GTGAAGTGAGGG 
CTCCCATA;GAPDH-Fw_5':CCATCTTCCAGGAGCGAGAT; GAPDH-Rv_5': TTCTCCATGGTG 
GTGAAGAC. The target gene value was normalized to the expression of the endogenous reference 
(GAPDH). A negative (without a prior reverse transcription reaction) control was always included. 
After amplification, 25 µL of each PCR mix was electrophoresed through a 2% (w/v) agarose gel with 
ethidium bromide (0.1 µg/mL) and visualized under an ultraviolet trans-illuminator (BioRad). The 
specific bands were analyzed by densitometry and the ratio with GAPDH expression was determined 
(all PCR amplifications were performed from 4 different experiments).  
3.5. Giemsa Staining 
ASCs were fixed in 4% paraformaldehyde at room temperature for 10 min and washed with PBS before 
incubating in Giemsa solution (Sigma, St. Louis, MO, USA) for 30 min. The excess stain was removed by 
subsequent washes with distilled water. The cells were allowed to air dry and then visualized under 
the microscope.  




3.6. CLMA Scaffolds Preparation  
Poly(methyl methacrylate) (PMMA) microspheres with a diameterof 90 ± 10 μm (Colacryl dp 300) 
were used as porogens by introducing them between two plates (of a self-built device whose distance 
could be controlled) and heating at 180 °C for 30 minutes to obtain the first template. This template 
shows the highest porosity attainable (that will yield the lowest porosity of the scaffold) with classical 
compaction values of 60%–65% for random mono-sized spherical particles. To obtain scaffolds with 
controlled porosity, the thickness of the obtained disk was first measured; then the disk was replaced in 
the mould and compressed at 180 °C for 30 min. The degree of compression was quantified by 
measuring the reduction in thickness. After cooling the template at room temperature, a mixture of 
caprolactone 2-(methacryloyloxy) ethyl ester (CLMA, as monomer), benzoin (1 wt %, as initiator) and 
ethylene glycol dimethacrylate (1 wt %, EGDMA) was introduced in the empty space between the 
PMMA spheres. The polymerization was carried out up to limiting conversion under a UV radiation 
source at room temperature. After polymerization took place, the porogen template was removed by 
Soxhlet extraction with acetone for 48 hours. The porous sample was maintained in Soxhlet with 
ethanol in order to extract low molecular weight substances for an additional 24 hours. Samples were 
dried in a vacuum to constant weight before characterization. 
3.7. Morphological Characterization of CLMA Scaffolds  
Morphological analysis of CLMA scaffolds were examined in a scanning electron microscope Jeol 
JSM-5410, SEM. All specimens were coated with a conductive layer of sputtered gold. The 
micrographs were taken at an accelerating voltage of 20 kV in order to ensure a suitable image 
resolution. When cells were seeded onto CLMA scaffolds before SEM analysis a previous fixation 
with 2.5% PFA plus 2% glutaraldehyde for 10 min at RT was performed and then dehydrated in 
graded ethanol concentrations. Critical point dryer (CPD) was performed on an Autosambri 
814 instruments (Rockville, MD, USA) followed by sputter coated with gold before observation.  
3.8. Immunocytochemistry 
Single cells (5 × 105) were distributed in 2 µL per 2 mm2 CLMA scaffold (previously re-hydrated 
by overnight incubation in cell culture medium at 37 °C) or alone (without scaffold) individually set 
into 96 well plates, and incubated for 24 hours. Then ASCs were treated with 0 or 5% PRGF for an 
additional 24 hours in growth medium in the absence of FBS and with 2 Units/ml of heparin. 
Subsequently, the cells were fixed with 4% paraformaldehyde at room temperature for 10 min and 
washed with PBS, permeabilized with a PBS solution containing 0.1% Triton X-100 and blocked with 
5% goat serum in PBS for 1 h. The following primary antibodies were diluted in blocking solution and 
incubated overnight at 4 °C. Vimentin (α-mouse, clone V9 Cat. MAB3400; Millipore, Billerica, MA, 
USA (1:200)) and P-Histone3-Alexa 647 (α-rabbit, Cat. 9716S; Cell Signaling, Boston, USA (1:100)). 
After being rinsed three times with PBS, the cells were incubated with Oregon Green-Alexa647 dye 
conjugated goat anti-mouse IgG 1:400 (Life Technologies S.A., Alcobendas, Spain) secondary 
antibodies for 1 hour at room temperature. All cells were counterstained by incubation with  
4,6-diamidino-2-phenylindole dihydrochloride (DAPI) from Molecular Probes (Invitrogen, Carlsbad, 




CA, USA) for 3 min at room temperature followed by washing steps. Samples were mounting using 
FluorSave Reagent (Calbiochem, Darmstadt, Germany). Signals were visualized by Confocal 
Microscopy (Leica Microsistemas, Barcelona, Spain). Four different assays were performed and at 
least 6 different fields per condition and assay were analyzed.  
3.9. Statistical Analysis 
Statistical comparisons were assessed by Student’s t-test. All P values were derived from a  
two-tailed statistical test using the SPSS 11.5 Software. A P-value < 0.05 was considered 
statistically significant.  
4. Conclusions  
We propose the use of a new strategy that combines the direct implantation of autologous cASCs, 
obtained and amplified in aseptic conditions, into CLMA proliferative scaffolding structures improved 
by autologous PRGF addition. This strategy offers the ability to rapidly obtain cASCs in aseptic 
conditions required for clinical application and reduces the need of massive proliferation and 
amplification of stem cells by successive culturing. In addition, this proposal avoids further 
chemotaxis of stem cells into the damaged tissue by in situ substitution of the affected tissue with the 
synthetic scaffold CMLA, which has positive osteoconductive properties [34]. The uniform porosity of 
CMLA maintains stem cells with homogeneous distribution and allows cASCs to continue with basic 
biological processes as proliferation. Despite superior biocompatibility of CMLA and the promising 
results observed after treatment of cASC with PRGF in vitro, additional experimentation in vivo is 
required for further translational approaches of the proposed framework to the clinic. Moreover the 
present data significantly contributes to improve the design of osteoarticular combinatory cell-based 
therapies where PRGF contributes to enhance stem cell survival in a well adaptable scaffold niche.  
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